



Attorney Docket: 119.002

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Irving M Fishman  
Type or Print Name

*Irving M Fishman*  
Signature

December 1, 2003  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Awad

Group Art Unit:

Examiner:

SERIAL NO: 10/646,122

FILED: August 22, 2003

FOR: CROSS-LINKED SILICONE GELS;  
PRODUCTS CONTAINING THE SAME; AND  
METHODS OF MANUFACTURE THEREOF

Box Non-Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CORRECTED**  
**INFORMATION DISCLOSURE STATEMENT**

Sir:

Further to the Information Disclosure Statement filed in the above identified Application on November 20, 2003, Applicant noted some errors in the Table on page 3. This paper corrects those errors and should be considered in place of the Table submitted in the document filed on November 20, 2003. In addition to the corrections in the Table, a typographical error has been corrected in the text commenting on the Table and as such, all of the comments on the Table are reproduced here with the typographical correction made. No new prior art references are being submitted. Thus, the examiner is respectfully requested to consider the previously submitted Information Disclosure Statement as corrected by this paper. Since this is merely a

correction to the timely filed Information Disclosure of 11/20/2003, Applicant submits that no fee is due. In addition, as this paper is being submitted before the issuance of a first action (and in fact less than 2 weeks after the submission of the original Information Disclosure Statement), Applicant submits that there is no fee due with this paper. If this paper will not be considered without a fee or further materials from Applicant, the Examiner is respectfully requested to advise the undersigned as soon as possible so that such deficiency may be addressed at the earliest possible time.

			<u>Form</u> <u>#</u>												
<b><u>Component</u></b>	Form A	Form B	Form C	Form D	Form E	Form F	Form G	Form H	Form. I	Form J	Form K	Form L	Form M	Form N	Form O
Divinyl PDMS <sup>1</sup>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PDPDMS <sup>5</sup>					+	+	+								
MHPS <sup>2</sup>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pt catalyst	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tetrameric cyclomethicone		+			+					+					
Pentameric cyclomethicone			+			+					+	+	+		+
Linear PDMS <sup>3</sup>				+			+	+	+						
Linear PDMS <sup>4</sup>										+	+				
Isododecane	+														
<b><u>Diluted with</u></b>	+					+	+		+			+	+	+	+
Linear DMS <sup>3</sup>							+	+	+						
Pentameric cyclomethicone						+						+	+		+
Isododecane	+								+						
Hydrogenated Polyiso-butene														+	+
<b>Total Polymer</b>	5.2	6	6	6	12.6	12.6	12.6	5.7	5.9	4.5	4.5	4.1	2.3	4.2	3.9

<sup>1</sup>Divinyl terminated polydimethylsiloxane

<sup>2</sup>Methyl hydrogen polysiloxane

<sup>3</sup>Linear polydimethyl siloxane 5centistokes

<sup>4</sup>Linear polydimethyl siloxane 1000 centistokes

<sup>5</sup>Diviyl terminated polydiphenyldimethylsiloxane

Formulation A was first quoted for sale on 6/4/02, more than a year before the present application date, but less than 1 year before Applicant's provisional application.

Formulation B was quoted for sale based on a product that did not control the shear during manufacture more than a year before the filing date of Applicant's provisional application.

Formulation C was first quoted for sale based on a product that was made without controlling shear during manufacture more than a year before the filing date of Applicant's Provisional Application. Beginning in May 2002, Formulation C was quoted for sale for a product that did control the shear in accordance with the present application and applicant's Provisional Application.

Formulation D was quoted for sale only based on a product that did not control the shear during manufacture more than a year before the filing date of both the present application and Applicant's Provisional Application.

Formulation E, F, and G were quoted for sale only based on a product that did not control the shear during the manufacture more than a year before the filing date of both the present application and Applicant's Provisional Application.

Formulations H and I are merely formulation D further diluted. These formulations were quoted for sale only based on a product that did not control the shear during manufacture more than a year before the filing date of both the present application and Applicant's Provisional Application.

Formulations J and K do not appear to have been sold or offered for sale, but were merely experimental in nature. However, in order to be as forthcoming with the Examiner as possible, Applicant discloses the possibility that further investigation of Applicant's files concerning these formulations may reveal an offer for sale date. These formulations were made without control of the shear during manufacture.

Formulation L was first quoted for sale on 8/16/02 (based on a product that was made without control of shear during manufacture) more than a year before the present application filing date, but less than a year before applicant's Provisional Application.

Formulation M is a modified version of formulation L where shear was controlled in formulation M during manufacture. It was first quoted for sale before the present application filing date and provisional filing date, but less than 1 year before Applicant's provisional filing date.

Formulation N was first quoted for sale on 5/8/02, more than a year before the present application filing date, but less than 1 year before the filing date of applicant's Provisional Application.


Formulation O is a modification of formulation N (in which shear was controlled in Formulation O and in which additional pentameric cyclomethicone was added as a diluent as compared to Formulation N). Formulation O was first offered for sale before the filing date of the present application, but less than 1 year before the filing date of Applicant's Provisional Application.

89 Headquarters Plaza  
Suite 1422, North Tower  
Morristown, NJ 07960

Tel: (973) 285-1548  
Fax: (973) 993-1857

Date: December 1, 2003

Respectfully submitted,



Irving M. Fishman  
Reg. No. 30,258  
Attorney for Applicant